In this report, we present a unique case of a 75-year-old Chinese man who developed ipsilateral orolingual angioedema following the administration of rhTNK-tPA for AIS. Our case emphasizes the need for caution when using rhTNK-tPA due to its potential to induce ipsilateral orolingual angioedema...
2. Tian DC, Shi K, Zhu Z, Yao J, Yang X, Su L, Zhang S, Zhang M, Gonzales RJ, Liu Q, Huang D, Waters MF, Sheth KN, Ducruet AF, Fu Y, Lou M, Shi FD. Fingolimod Enhances the Efficacy of Delayed Alteplase Adminis...
Before tPA administration, you will undergo a computed brain tomography (CT) scan. This is because it is hazardous for some patients to receive due to having one of the following health conditions: Hemorrhagic stroke Brain aneurysm or AVM Head injuries Bleeding or blood clotting disorders Bleedi...
Based on evidence that the administration of IV tissue plasminogen activator (tPA) improved the outcomes of selected patients with acute ischemic stroke, the US Food and Drug Administration (FDA) approved its use for this purpose in 1996, leading to a revolution in stroke care.1 Following its ...
In the article below, we'll teach youhow to calculate the tPA dose for a stroke- we'll also talk about possible alteplase antidote and present the basic rules oftPA administration. 💉 ❗ Remember, our tool cannot be used as the one and only source of clinical knowledge -always double...
(AIEgens), which exhibit better tracking ability than the commercially available tracer DiR. Moreover, tPA administration promoted the homing of MSC-EVs to the ischemic brain and increased the uptake of MSC-EVs by astrocytes...
Errors often arise because of confusion between the abbreviation TNK and tPA, which has resulted in TNKase being given to stroke patients instead of the intended Activase. While TNKase is now approved for stroke treatment, dosing and administration protocols differ between the medications. ...
Localized left atrial administration of tpa for the treatment of mechanical mitral valve thrombosis. Catheter Cardiovasc Interv 2008;72:151-5.Desai S, Kavinsky C. Localized left atrial administration of tPA for the treatment of mechanical mitral valve thrombosis. Catheter Cardiovasc Interv. 2008;72:...
Conclusion IV-tPA administration for LVO has a low rate of primary recanalization with risk of distal embolic phenomenon often still requiring MT. No significant changes in patient outcomes were noted in this study due to clot migration. Larger studies will be necessary to determine if IV-tPA ...
摘要:组织型纤溶酶原激活剂(ｔｉｓｓｕｅｔｙｐｅｐｌａｓｍｉｎａｃｔｉｖａｔｏｒꎬｔＰＡ)是美国食品药品监督管理局唯一批准的用于急性缺血性卒中治疗的药物ꎬ但由于治疗时间窗狭窄以及会导致严重的出血性转化(ｈｅｍｏｒｒｈａｇｉｃｔｒａｎｓｆｏｒｍａｔｉｏｎꎬＨＴ)ꎬ其临床应用受到限制ꎮ本文拟从血脑屏障破坏...